WO2007030451A3 - Antibodies as t cell receptor mimics, methods of production and uses thereof - Google Patents

Antibodies as t cell receptor mimics, methods of production and uses thereof Download PDF

Info

Publication number
WO2007030451A3
WO2007030451A3 PCT/US2006/034547 US2006034547W WO2007030451A3 WO 2007030451 A3 WO2007030451 A3 WO 2007030451A3 US 2006034547 W US2006034547 W US 2006034547W WO 2007030451 A3 WO2007030451 A3 WO 2007030451A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
antibodies
mhc
cell receptor
interest
Prior art date
Application number
PCT/US2006/034547
Other languages
French (fr)
Other versions
WO2007030451A2 (en
Inventor
Jon A Weidanz
Vaughan Wittman
Original Assignee
Receptor Logic Ltd
Jon A Weidanz
Vaughan Wittman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Receptor Logic Ltd, Jon A Weidanz, Vaughan Wittman filed Critical Receptor Logic Ltd
Priority to AU2006289683A priority Critical patent/AU2006289683A1/en
Priority to CA002662798A priority patent/CA2662798A1/en
Priority to EP06814164A priority patent/EP1933864A4/en
Publication of WO2007030451A2 publication Critical patent/WO2007030451A2/en
Priority to IL190014A priority patent/IL190014A0/en
Publication of WO2007030451A3 publication Critical patent/WO2007030451A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to a methodology of producing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies will mimic the specificity of a T cell receptor (TCR) but will have higher binding affinity such that the molecules may be used as therapeutic, diagnostic and research reagents. The method of producing a T-cell receptor mimic of the present invention includes identifying a peptide of interest, wherein the peptide of interest is capable of being presented by an MHC molecule. Then, an immunogen comprising at least one peptide/MHC complex is formed, wherein the peptide of the peptide/MHC complex is the peptide of interest. An effective amount of the immunogen is then administered to a host for eliciting an immune response, and serum collected from the host is assayed to determine if desired antibodies that recognize a three-dimensional presentation of the peptide in the binding groove of the MHC molecule are being produced. The desired antibodies can differentiate the peptide/MHC complex from the MHC molecule alone, the peptide alone, and a complex of MHC and irrelevant peptide. Finally, the desired antibodies are isolated.
PCT/US2006/034547 2005-09-07 2006-09-07 Antibodies as t cell receptor mimics, methods of production and uses thereof WO2007030451A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2006289683A AU2006289683A1 (en) 2005-09-07 2006-09-07 Antibodies as T cell receptor mimics, methods of production and uses thereof
CA002662798A CA2662798A1 (en) 2005-09-07 2006-09-07 Antibodies as t cell receptor mimics, methods of production and uses thereof
EP06814164A EP1933864A4 (en) 2005-09-07 2006-09-07 Antibodies as t cell receptor mimics, methods of production and uses thereof
IL190014A IL190014A0 (en) 2005-09-07 2008-03-06 Antibodies as t cell receptor mimics, methods of production and uses thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US71462105P 2005-09-07 2005-09-07
US60/714,621 2005-09-07
US75154205P 2005-12-19 2005-12-19
US60/751,542 2005-12-19
US75273705P 2005-12-20 2005-12-20
US60/752,737 2005-12-20
US83827606P 2006-08-17 2006-08-17
US60/838,276 2006-08-17

Publications (2)

Publication Number Publication Date
WO2007030451A2 WO2007030451A2 (en) 2007-03-15
WO2007030451A3 true WO2007030451A3 (en) 2009-04-16

Family

ID=37836380

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/034547 WO2007030451A2 (en) 2005-09-07 2006-09-07 Antibodies as t cell receptor mimics, methods of production and uses thereof

Country Status (5)

Country Link
EP (1) EP1933864A4 (en)
AU (1) AU2006289683A1 (en)
CA (1) CA2662798A1 (en)
IL (1) IL190014A0 (en)
WO (1) WO2007030451A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2656583A1 (en) * 2006-06-01 2007-12-13 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
EP2262834A4 (en) * 2008-02-27 2011-08-17 Receptor Logic Inc Antibodies as t cell receptor mimics, methods of production and uses thereof
UA114108C2 (en) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679641A (en) * 1992-05-26 1997-10-21 Rijksuniversiteit Leiden Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes
US5726023A (en) * 1993-03-17 1998-03-10 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US20030165513A1 (en) * 2000-12-04 2003-09-04 Venky Ramakrishna Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20030223994A1 (en) * 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2004101607A2 (en) * 2003-05-13 2004-11-25 Hildebrand William H Comparative ligand mapping from mhc class i positive cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0113213A (en) * 2000-08-14 2003-07-08 Akzo Nobel Nv Method for diagnosing an autoimmune disease, antibody, diagnostic composition, and antibody use
FR2839452A1 (en) * 2002-05-07 2003-11-14 Pf Medicament USE OF PEPTIDE DERIVED FROM THE HCG BETA SUBUNIT TO GENERATE A CTL ANTITUMOR RESPONSE
US20060034850A1 (en) * 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679641A (en) * 1992-05-26 1997-10-21 Rijksuniversiteit Leiden Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes
US5726023A (en) * 1993-03-17 1998-03-10 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5968513A (en) * 1996-06-24 1999-10-19 University Of Maryland Biotechnology Institute Method of promoting hematopoiesis using derivatives of human chorionic gonadotropin
US20030165513A1 (en) * 2000-12-04 2003-09-04 Venky Ramakrishna Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20030223994A1 (en) * 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
WO2004101607A2 (en) * 2003-05-13 2004-11-25 Hildebrand William H Comparative ligand mapping from mhc class i positive cells

Also Published As

Publication number Publication date
AU2006289683A1 (en) 2007-03-15
EP1933864A4 (en) 2009-12-16
WO2007030451A2 (en) 2007-03-15
CA2662798A1 (en) 2007-03-15
IL190014A0 (en) 2008-08-07
EP1933864A2 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
WO2005116072A3 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
US11092601B2 (en) Methods for detecting peptide/MHC/TCR binding
Dhanda et al. Novel in silico tools for designing peptide-based subunit vaccines and immunotherapeutics
DeLong et al. Ara h 1–reactive T cells in individuals with peanut allergy
CA2972306C (en) Method for the absolute quantification of naturally processed hla-restricted cancer peptides
Schirle et al. Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens
WO2011128448A1 (en) Method for differentially quantifying naturally processed hla-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
Shahine et al. A T-cell receptor escape channel allows broad T-cell response to CD1b and membrane phospholipids
NZ584558A (en) Peptide-lipid constructs and their use in diagnostic and therapeutic applications
Archila et al. Grass‐specific CD 4+ T‐cells exhibit varying degrees of cross‐reactivity, implications for allergen‐specific immunotherapy
Dørum et al. HLA-DQ molecules as affinity matrix for identification of gluten T cell epitopes
Fulton et al. Immunoproteomics: current technology and applications
Zhang et al. Rapid screening for potential epitopes reactive with a polycolonal antibody by solution-phase H/D exchange monitored by FT-ICR mass spectrometry
JP4979593B2 (en) Means and methods for breaking non-covalent interactions between molecules
WO2007030451A3 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
Nony et al. Proteomics for allergy: from proteins to the patients
Gengenbacher et al. Mycobacterium tuberculosis in the Proteomics Era
ES2463828T3 (en) Hypoallergenic hybrid polypeptides for allergy treatment
Hare et al. Direct identification of HLA‐presented CD8 T cell epitopes from transmitted founder HIV‐1 variants
Sette et al. Class I molecules with similar peptide-binding specificities are the result of both common ancestry and convergent evolution
Wang et al. Recent progress on MHC-I epitope prediction in tumor immunotherapy
Graner et al. The ‘peptidome’of tumour-derived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity
Inoue et al. Discovery of an α2, 9-polyNeu5Ac glycoprotein in C-1300 murine neuroblastoma (clone NB41A3)
WO2022133347A2 (en) Display of peptide-mhc (pmhc) on multimeric protein scaffolds and uses thereof
WO2006086288A3 (en) Methods for reducing the symptoms of autoimmunity and inflammation using binding proteins against antigens exposed on dead or dying cells

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 190014

Country of ref document: IL

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006289683

Country of ref document: AU

Ref document number: 2006814164

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006289683

Country of ref document: AU

Date of ref document: 20060907

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2662798

Country of ref document: CA